Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars

FDA is ending one of the landmark drug safety programs from the REMS era, announcing it has released Amgen from its mandatory obligations for the erythropoiesis-stimulating agent (ESA) class. The decision comes just ahead of the likely approval of the first biosimilar application in the class.

FDA’s decision to end the erythropoiesis-stimulating agent (ESA) class REMS is yet another symbolic milestone for the agency in moving beyond the drug safety debates of the 2000s – and also a timely step to help advance the emerging era of biosimilars.

FDA announced April 13 that it is releasing Amgen from its formal Risk-Evaluation and Mitigation Strategy obligations for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet